Program badawczy SARSTer

SARSTer jest retrospektywnym, nieinterwencyjnym programem badawczym finansowanym ze środków Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych oraz Agencji Badań Medycznych, we współpracy z firmą Tiba. Celem badania jest ocena skuteczności i bezpieczeństwa różnych opcji terapii COVID-19 stosowanych w Polsce u chorych leczonych począwszy od 1 marca 2020. Szczególny nacisk został położony na terapie zalecane w rekomendacjach PTEiLChZ, co pozowoli na ich doskonalenie. Uzyskane dane będą analizowane, w zależności od wielu parametrów wyjściowych i z uwzględnieniem różnych punktów końcowych oceniających skuteczność terapii. Badanie jest realizowane na platformie internetowej wykorzystywanej uprzednio w projektach EpiTer-2 i EpiGeneS we współpracy z firmę Tiba. W projekcie uczestniczy 30 polskich ośrodków leczących zakażenia SARS-CoV-2, w tym 10 pediatrycznych. Podstawowym kryterium włączenia jest rozpoznanie COVID-19. Dodatkowe kryteria będą zależne od cząstkowych analiz, których celem będzie opracowanie danych do publikacji. Pozyskane dzięki SARSTer informacje pozwolą na zoptymalizowanie postępowania terapeutycznego w COVID-19.

1) Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study

2) Remdesivir based therapy improve significantly recovery of patients with COVID-19 in the SARSTer multicentre, real world experience study.

3) Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study

4) Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis

5) Impact of Kidney Failure on the Severity of COVID-19  

6) Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine

7) Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study

8) Pneumonia, gastrointestinal symptoms, comorbidities, and coinfections as factors related to a lengthier hospital stay in children with COVID-19—analysis of a paediatric part of Polish register SARSTer.

9) Clinical and Epidemiological Characteristics of 1283 Pediatric Patients with Coronavirus Disease 2019 during the First andSecond Waves of the Pandemic—Results of the Pediatric Part of a Multicenter Polish Register SARSTer

10) Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination

11) Demographic and clinical overview of hospitalized COVID-19 patients during the first 17 months of the pandemic in Poland 

12) Does Hospitalization Change the Perception of COVID-19 Vaccines among Unvaccinated Patients?

13) Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

14) Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)

15) The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland

16) Air pollution might affect the clinical course of COVID-19 in pediatric patients

17) Real‑world experience with molnupiravir during the period of SARS‑CoV‑2 Omicron variant dominance 

18) Remdesivir decreases mortality in COVID-19 patients with active malignancy

19) The course of COVID-19 in patients with systemic autoimmune rheumatic diseases

20) Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database

21) Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings

22) Clinical Course and Severity of COVID-19 in 940 Infants with and without Comorbidities Hospitalized in 2020 and 2021: The Results of the National Multicenter Database SARSTer-PED

23) Differences between the course of SARS‑CoV‑2 infections in the periods of the Delta and Omicron variant dominance in Poland 

24) Short‐term exposure to ambient air pollution and COVID‐19 severity during SARS‐CoV‐2 Delta and Omicron waves: A multicenter study 

25) Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant

26) Differences in Clinical Presentation of COVID-19 in Children Hospitalized During Domination of Early (BA.1, BA.2) and Late (BA.5, BA.2.75, BQ.1 and XBB.1.5) SARS-CoV-2 Omicron Subvariants